**International Journal of Pharmaceutical and Bio-Medical Science**

ISSN(print): 2767-827X, ISSN(online): 2767-830X

Volume 03 Issue 07 July 2023

Page No: 369-375

DOI: https://doi.org/10.47191/ijpbms/v3-i7-10, Impact Factor: 6.858

# Immunological Approaches for Diagnosis and Treatment of Kidney Failure: A Systematic Review

**Abdullah Salim Al-Karawi[1], Maha Khalid Khadhum[2], Yamama Farouk Alawssi[3]**

[1] Department of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq

[2,3] Ibn Sina University of Medical and Pharmaceutical Sciences, Baghdad, Iraq

**ABSTRACT**

Kidney failure is a severe health issue with ramifications for the general population. An overview of the significance of efficient diagnostic and therapeutic methods in resolving this issue is provided in this abstract. Various immune cells, cytokines, and inflammatory processes that contribute to renal injury are highlighted in the discussion of the function of immune system dysregulation in kidney failure. To create focused interventions, it is essential to comprehend these mechanisms. The merits, drawbacks, and prospective clinical applications of immunological markers and methods for renal failure diagnosis are discussed. For prompt intervention and management, an accurate diagnosis is essential. The effectiveness, mechanisms of action, and potential negative consequences of various immunotherapeutic approaches to treating renal failure are examined. Immunotherapy developments give patients hope for better outcomes. Immunological techniques for diagnosing and treating kidney failure are addressed, along with any current implementation obstacles. Potential research areas are recommended to address these issues and enhance patient outcomes. Future directions will spur innovation and development in this area.

**ARTICLE DETAILS**

**Published On:**
25 July 2023

**Available on:**
**https://ijpbms.com/**

## 1. INTRODUCTION

Kidney failure, or renal failure, is a significant global health concern affecting millions of individuals worldwide. It is characterized by the loss of kidney function, leading to the accumulation of waste products and disruption of crucial fluid and electrolyte balance. Improving patient outcomes in renal failure depends on developing efficient diagnostic methods and therapeutic strategies (1).

In recent years, there has been growing recognition of the role played by immunological mechanisms in kidney failure. Immune system dysregulation can contribute to renal damage through various processes involving immune cells, cytokines, and inflammatory responses (2). Understanding these immunological mechanisms holds promise for advancing diagnostic and therapeutic strategies in kidney failure.

This systematic review offers an in-depth assessment of immunological strategies used in kidney failure diagnosis and treatment. It aims to investigate the complex interactions between immune system elements and the development of kidney injury (2, 3). We want to clarify how these immunological techniques have altered our understanding of kidney failure care by synthesizing results from recent investigations.

Additionally, this review will review cutting-edge diagnostic methods that use immunological markers or tools to pinpoint early indications of kidney disease (4, 5). It will additionally look at new immunotherapeutic approaches used to treat kidney failure patients, offering light on their underlying mechanisms and potential advantages (6).

Despite significant advancements in this area, several obstacles prevent the widespread practical application of immunological methods for detecting and treating renal failure. These difficulties include restrictions on present methods, potential negative consequences of treatments, and barriers to adopting personalized medicine. To overcome these obstacles and provide new lines of inquiry for ongoing research aiming at improving these immunological strategies, this review will do just that.

This systematic review seeks to advance knowledge and encourage additional investigation in the quickly developing field of immunology by critically reviewing the state of immunological techniques in kidney failure diagnosis and treatment. Ultimately, we hope that our comprehensive analysis will pave the way for more effective diagnostic and treatment strategies, leading to improved outcomes for patients with kidney failure.

## 2. OVERVIEW OF IMMUNOLOGICAL MECHANISMS IN KIDNEY FAILURE

The pathogenesis of kidney failure involves intricate interactions between immune cells, cytokines, and inflammatory processes. The development of kidney failure and kidney damage can both be impacted by immune system dysregulation. We will give an outline of the immunological pathways linked to renal failure in this section.

### 2.1. Immune Cell Infiltration:

The promotion of inflammation and tissue damage is significantly aided by infiltrating immune cells into the kidneys, such as T lymphocytes, macrophages, and neutrophils (7). These immune cells discharge cytokines and chemokines that promote localized inflammation and worsen kidney damage (8).

### 2.2 Cytokine Imbalance:

The balance between pro-inflammatory and anti-inflammatory cytokines is disrupted in kidney failure. Overproduction of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β), exacerbates renal inflammation and contributes to tissue injury. Interleukin-10 (IL-10) is an example of an anti-inflammatory cytokine whose production is inadequate or whose function is compromised, which impedes inflammation's ability to resolve (9-11).

### 2.3 Complement System Activation:

Complement system activation is a critical immunological process that also plays a role in renal failure. The increased complement activation resulting from complement component dysregulation worsens renal failure by triggering inflammatory reactions and tissue damage (12-14).

### 2.4. Autoimmunity:

Certain kinds of kidney failure, such as autoimmune glomerulonephritis, are strongly impacted by autoimmune processes (15, 16). In this situation, particular kidney antigens become autoantibody targets. This could result in the accumulation of immune complexes, activation of the complement system, and subsequent inflammation (17).

The pathophysiology of kidney failure can be better understood by understanding these immunological pathways, making it simpler to create individualized therapy regimens. The following sections will discuss the prospect that renal failure can be identified and treated using immunological methods.

## 3. IMMUNOLOGICAL APPROACHES FOR DIAGNOSIS AND TREATMENT

In this part, we will investigate the immunological methods used to identify and treat renal failure. We'll look at the most recent developments in diagnostic techniques that use immunological markers or tools. We will also examine novel immunotherapy strategies for efficiently managing patients with renal failure.

### 3.1. Cystatin C:

Advantages: Cystatin C is considered a more accurate predictor of renal function than creatinine, especially in individuals with normal muscle mass or those in the early stages of kidney disease (18)

Limitations: It's crucial to remember that age, weight, and inflammation generally impact cystatin C levels less than they do on creatinine levels. Nevertheless, it is susceptible to the effects of various medications and other disorders, such as thyroid problems.

Clinical application potential: Cystatin C has demonstrated potential in assessing renal function and glomerular filtration rate (GFR) in various groups. Young, old, obese, or diabetic are all affected by this.

### 3.2. Urinary albumin-to-creatinine ratio (ACR) (19):

Advantage: The Albumin-to-Creatinine Ratio (ACR) is a commonly utilized indicator for the early identification of kidney damage brought on by conditions like diabetic nephropathy or hypertensive nephrosclerosis.

Limitations: It's important to remember that factors like urinary tract infections (UTIs), exercise, or a high-protein diet can influence ACR levels. Additionally, ACR is unable to differentiate between various causes of albuminuria.

Potential uses in medicine ACR screening are indicated to identify renal impairment and monitor the condition's progression in persons with diabetes or high blood pressure.

### 3.3. Anti-glomerular basement membrane (anti-GBM) antibodies (20):

Advantages: These antibodies are highly accurate diagnostic tools for autoimmune diseases like Goodpasture's syndrome, which typically causes fast-progressing glomerulonephritis.

Limitations: Not all autoimmune kidney illnesses affect the kidneys, and the presence of anti-GBM antibodies does not automatically rule out renal involvement.

Potential clinical applications: Determining the presence of anti-GBM antibodies is crucial for validating the diagnosis of autoimmune kidney diseases and formulating successful treatment regimens.

### 3.4. Complement component levels (C3, C4) (21):

Advantages: Abnormal complement component levels can signal kidney damage caused by autoimmune diseases such lupus nephritis or membranoproliferative glomerulonephritis.

Limitations: The sensitivity and specificity of complement component assays can vary depending on the underlying illness and disease activity.

Potential clinical applications: Measuring complement components aids in the diagnosis and monitoring of several renal diseases associated with immune system dysfunction.

### 3.5. Human leukocyte antigen (HLA) typing (22):

Advantages: For autoimmune conditions like Goodpasture's syndrome, which frequently results in fast progressing

glomerulonephritis, these antibodies act as extremely accurate diagnostic instruments.

Limitations: It's important to recognize that not all autoimmune kidney disorders affect the kidneys, and the presence of anti-GBM antibodies does not necessarily indicate renal involvement.

Potential clinical applications: Pre-transplant evaluation, which includes HLA typing, helps to lower the risk of organ rejection and boost graft survival rates over the long term.

**3.6. Urine Protein Electrophoresis (23):**

Advantages: Urine protein electrophoresis can diagnose kidney diseases by identifying the different protein types that are present in urine.

Limitations: It might not be able to discriminate between proteins with similar patterns or detect low amounts of some proteins.

Potential clinical uses: This method is especially helpful in detecting proteinuria patterns linked to diseases like multiple myeloma or monoclonal gammopathy of renal relevance.

**3.7. Anti-neutrophil cytoplasmic antibodies (ANCA) (24):**

Advantages: ANCA testing is useful for identifying and categorizing different types of vasculitis, including ANCA-associated glomerulonephritis.

Limitations: False positive results can happen, and ANCA alone cannot prove a diagnosis; clinical findings must also be correlated.

Potential clinical uses: ANCA testing aids in identifying the various forms of glomerulonephritis and directs the best course of treatment.

**3.8. Anti-nuclear Antibodies (ANA) (25, 26):**

Advantages: The utilization of ANA (Antinuclear Antibody) testing proves advantageous in identifying autoimmune kidney diseases, such as lupus nephritis and renal involvement associated with systemic sclerosis.

Limitations: It is important to note that positive ANA test results must be carefully correlated with clinical symptoms and other laboratory findings to establish a definitive diagnosis. Potential therapeutic applications:

ANA testing holds significant potential in determining the optimal treatment approach for autoimmune diseases that result in kidney damage. It serves as a critical component within the diagnostic process.

**3.9. Renal Biopsy (27, 28):**

Advantages: Renal biopsy is an essential technique for acquiring kidney tissue samples, facilitating direct observation and microscopic analysis to identify the root causes of kidney failure.

Limitations: It is crucial to acknowledge that renal biopsy, as an invasive surgical procedure, carries inherent risks of complications, including bleeding and infection.

Potential therapeutic applications: Renal biopsies hold significant potential as a diagnostic tool in evaluating various renal diseases, including vasculitis, interstitial nephritis, and glomerular diseases.

**3.10. Antinuclear Antibodies (ANCA) Subtypes (29, 30):**

Advantages: The differentiation of ANCA subtypes, such as anti-proteinase 3 (PR3) or anti-myeloperoxidase (MPO), plays a valuable role in distinguishing different types of vasculitis that present with renal involvement.

Limitations: It is essential to carefully consider clinical observations alongside the presence of ANCA, as the presence of ANCA alone is insufficient to establish a definitive diagnosis.

Potential clinical applications: The identification of ANCA subtypes proves instrumental in the diagnosis and classification of small-vessel vasculitis, particularly pauci-immune glomerulonephritis.

**3.11. Anti-Double Stranded DNA Antibodies (anti-dsDNA) (31, 32):**

Advantages: Detection of anti-dsDNA antibodies is highly specific for systemic lupus erythematosus (SLE) and lupus nephritis.

Limitations: Levels of anti-dsDNA antibodies may fluctuate over time, and their absence does not exclude SLE or lupus nephritis.

Potential clinical applications: Testing for anti-dsDNA antibodies helps establish the diagnosis and monitor disease activity in SLE patients with renal involvement.

**3.12. Serum Complement Factor Levels (33, 34):**

Advantages: Quantification of complement factors, such as C1q, C2, C3, C4, allows assessment of complement system activation and dysfunction associated with various kidney diseases.

Limitations: Abnormal complement levels need to be interpreted alongside clinical data as they can occur in other conditions unrelated to kidney disease.

Potential clinical applications: Measurement of complement components aids in the diagnosis and monitoring of complement-mediated glomerulopathies like membranoproliferative glomerulonephritis or atypical hemolytic uremic syndrome.

**3.13. Anti-Phospholipase A2 Receptor Antibodies (anti-PLA2R) (35)**

Anti-Phospholipase A2 Receptor Antibodies (anti-PLA2R) (35)

Advantages: Detection of anti-PLA2R antibodies is highly specific for primary membranous nephropathy, a common cause of nephrotic syndrome.

Limitations: Not all cases of primary membranous nephropathy are associated with anti-PLA2R antibodies, and the clinical significance of these antibodies in disease prognosis is still evolving.

Potential clinical applications: Testing for anti-PLA2R antibodies aids in diagnosing primary membranous nephropathy and monitoring response to therapy.

### 3.14. Imaging Techniques (36):

Advantages: Imaging modalities like ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) can provide valuable anatomical information about the kidneys and help identify structural abnormalities or assess disease progression.

Limitations: Imaging findings are often nonspecific and need to be correlated with clinical history and other diagnostic tests for accurate interpretation.

Potential clinical applications: Imaging techniques play a role in evaluating kidney size, detecting cysts, tumors, or obstructions, and guiding interventions such as renal biopsy or percutaneous nephrostomy.

## 4. IMMUNOLOGICAL APPROACHES FOR TREATMENT

### 4.1. Immunosuppressive Medications (37):

Mechanism of Action: Immunosuppressive drugs such as corticosteroids, calcineurin inhibitors (e.g., cyclosporine, tacrolimus), and antimetabolites (e.g., mycophenolate mofetil) target various immune pathways to reduce inflammation and suppress the immune response against the kidneys.

Efficacy: These medications are effective in managing certain autoimmune kidney diseases like lupus nephritis or vasculitis-associated glomerulonephritis, helping to preserve renal function and alleviate symptoms.

Potential Side Effects: Common side effects include increased susceptibility to infections, hypertension, hyperglycemia, bone loss, and gastrointestinal disturbances.

### 4.2. Monoclonal Antibodies (38, 39)

Mechanism of Action: Monoclonal antibodies specifically target molecules involved in the pathogenesis of kidney diseases. For instance, rituximab targets the B cell's CD20 to remove it from circulation.

Effectiveness: By lowering autoantibody synthesis or altering the immune response, monoclonal antibodies have effectively treated diseases like anti-GBM illness or membranous nephropathy.

Potential Side Effects: Infusion responses, an increased risk of infections, and infrequent adverse severe events like progressive multifocal leukoencephalopathy (PML) are all possible side effects.

### 4.3. Cytokine Inhibition (40):

Mechanism of Action: Inhibitors targeting specific cytokines involved in kidney inflammation can help dampen the immune response. Examples include inhibitors of tumor necrosis factor-alpha (TNF-α) or interleukin-6 (IL-6).

Efficacy: Cytokine inhibitors have demonstrated effectiveness in treating a number of immune-mediated kidney illnesses, such as the glomerulonephritis brought on by rheumatoid arthritis when using anti-TNF-a medicines.

Potential Side Effects: Increased susceptibility to infections, infusion responses, and rare instances of significant adverse events including the reactivation of latent tuberculosis are all possible side effects.

### 4.4. Complement Inhibition (41, 42):

Mechanism of Action Complement inhibitors target the complement pathway specifically, which is where immune system-induced kidney injury originates. Eculizumab, which blocks complement component C5, is one example.

Efficacy: Complement inhibitors have demonstrated effectiveness in controlling disorders such as atypical hemolytic uremic syndrome or C3 glomerulopathy by inhibiting complement-mediated kidney damage.

Potential adverse effects: Possible adverse effects of complement inhibitors include rare cases of meningococcal infections, an increased risk of infections, and infusion responses.

### 4.5. Cell-Based Therapies (43, 44):

Mechanism of Action: Immunomodulatory cells, such as mesenchymal stem cells (MSCs) or regulatory T cells (Tregs), which can modulate the immune system and assist in tissue healing, are administered as part of cell-based treatment.

Efficacy: Early study points to possible advantages in managing renal diseases caused by the immune system. More research is required to assess their effectiveness and the most effective treatment modalities.

Potential Side Effects: Current studies are examining the safety profile of cell-based therapies, considering elements like immunogenicity or tumorigenicity.

### 4.6. Plasmapheresis (45):

Mechanism of Action: Plasmapheresis involves removing damaging autoantibodies or immune complexes that cause kidney damage by extracting plasma from the blood.

Effectiveness: Plasmapheresis has demonstrated particular value in treating fast-advancing autoimmune kidney diseases like glomerulonephritis or anti-GBM illness.

Potential Side Effects: Hypotension, citrate toxicity, allergic reactions, and infections associated to catheter placement are a few possible side effects of plasmapheresis.

### 4.7. Intravenous Immunoglobulin (IVIG) Therapy (46, 47)

Mechanism of Action: Immunoglobulins from healthy donors are combined in IVIG therapy, which can change the immune response and lessen inflammation.

Effectiveness: IVIG therapy has been successful in treating several immune-mediated kidney diseases, including glomerulonephritis and vasculitis-related nephropathy.

Potential Side Effects: IVIG therapy may have unfavorable infusion reactions, renal damage, thrombotic events, and increased susceptibility to infections as side effects.

### 4.8. Tumor Necrosis Factor-alpha (TNF-α) Inhibitors (48):

Mechanism of Action: TNF-alpha inhibitors work by inhibiting the activity of TNF, a cytokine involved in inflammation and tissue damage.

Efficacy: Glomerulonephritis linked to rheumatoid arthritis and other inflammatory kidney diseases has been successfully treated with TNF-alpha inhibitors.

Potential adverse effects: TNF-alpha inhibitor adverse effects may include the emergence of serious infections, infusion responses, localized reactions at the injection site, and, while uncommon, malignancy.

### 4.9. Janus Kinase (JAK) Inhibitors (49, 50):

Mechanism of Action: Several cytokines that are connected to immune-mediated kidney diseases signal through Janus kinases. Inhibiting JAK activity is how JAK inhibitor's function.

Effectiveness: JAK inhibitors have shown promising results in treating conditions like lupus nephritis and various types of glomerulonephritis.

Potential Side Effects: Unfavorable consequences could include a higher risk of infections, hematological abnormalities, elevated liver enzymes, and digestive issues.

### 4.10. Stem Cell Therapy (51):

Mechanism of Action: To stimulate tissue repair and control the immune response, stem cell treatment involves the introduction of cells with regenerative and immunomodulatory capabilities.

Efficacy: By possibly lowering inflammation, encouraging tissue regeneration, and enhancing kidney function, stem cell therapy shows promise for treating renal failure.

Potential Side Effects: The safety profile of stem cell therapy is currently being studied, and this includes considering the possibility of tumor development or immunological responses.

## 5. CHALLENGES AND FUTURE DIRECTIONS

### 5.1 Challenges in implementing immunological approaches for kidney failure diagnosis and treatment:

The variety of renal illnesses presents a significant obstacle. Creating universal immunological strategies that work for all patients is challenging because many underlying diseases can lead to kidney failure. To address this challenge, further investigation is necessary to pinpoint immunological markers or pathways shared by various kidney disorders.

The intricate role played by the immune system in renal disease presents another difficulty. It is difficult to identify precise targets for intervention due to the complex interactions between various immune cells, cytokines, and signaling pathways. Future studies should concentrate on deciphering these intricate pathways to find fresh treatment targets.

Creating reliable immunotherapies for renal failure involves additional difficulties concerning treatment vigilance. Currently, there is a lack of reliable biomarkers that can accurately track disease progression or assess treatment response. Efforts should be made to identify and validate robust biomarkers that can aid in monitoring the effectiveness of immunotherapies.

### 5.2 Potential areas of research to overcome these challenges and improve patient outcomes:

Further exploration of personalized medicine approaches could help address the heterogeneity of kidney diseases. By identifying specific immune profiles or genetic factors associated with different types of kidney failure, tailored immunological therapies could be developed for individual patients.

Investigating combination therapies involving immunotherapies and other therapeutic modalities (such as traditional medications or regenerative therapies) may hold promise in achieving synergistic effects and enhancing treatment outcomes. This area requires extensive preclinical and clinical studies to evaluate safety and efficacy.

Advancing our understanding of the role played by non-immune cells, such as renal epithelial cells or endothelial cells, in modulating immune responses within the kidneys will be crucial. This knowledge could reveal new therapeutic targets and strategies for immunological interventions.

Exploring the potential of nanotechnology-based drug delivery systems or novel drug formulations could improve the specificity, efficacy, and safety of immunotherapies. These approaches may enhance targeted delivery to the kidneys and minimize off-target effects.

In conclusion, addressing existing challenges in implementing immunological approaches for kidney failure diagnosis and treatment requires focused research efforts in areas such as personalized medicine, combination therapies, non-immune cell interactions, and innovative drug delivery systems. By overcoming these challenges, we can strive

towards improving patient outcomes and advancing the field of immunological approaches for kidney failure.

## AUTHOR CONTRIBUTIONS

Every author involved in this study made significant contributions to the planning and execution of the research, data collection, as well as data analysis and interpretation. They all had a hand in either writing the initial manuscript or critically reviewing it for key intellectual content. They approved its submission to the present journal and committed to being responsible for every aspect of the work.

**Acknowledgments**

We thank Mustansiriyah University in Baghdad/Iraq (http://uomustansiriyah.edu.iq) for its support to achievement this work.

## REFERENCES

I. Imig JD, Ryan MJ. Immune and inflammatory role in renal disease. Compr Physiol. 2013;3(2):957-76.
II. Singbartl K, Formeck CL, Kellum JA, editors. Kidney-immune system crosstalk in AKI. Seminars in nephrology; 2019: Elsevier.
III. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9(6):7204.
IV. Hasson D, Menon S, Gist KM. Improving acute kidney injury diagnostic precision using biomarkers. Pract Lab Med. 2022;30:e00272.
V. Tidmas V, Brazier J, Bottoms L, Muniz D, Desai T, Hawkins J, et al. Ultra-endurance Participation and Acute Kidney Injury: A Narrative Review. International Journal of Environmental Research and Public Health. 2022;19(24):16887.
VI. Manohar S, Jhaveri KD, Perazella MA. Immunotherapy-related acute kidney injury. Advances in Chronic Kidney Disease. 2021;28(5):429-37. e1.
VII. Bonavia A, Singbartl K. A review of the role of immune cells in acute kidney injury. Pediatric Nephrology. 2018;33:1629-39.
VIII. Kinsey GR, Li L, Okusa MD. Inflammation in acute kidney injury. Nephron Experimental Nephrology. 2008;109(4):e102-e7.
IX. -Stolc S, Potrykus M, Stankiewicz M, Kaska Ł, Małgorzewicz S. Pro-inflammatory profile of adipokines in obesity contributes to pathogenesis, nutritional disorders, and cardiovascular risk in chronic kidney disease. Nutrients. 2022;14(7):1457.
X. Zhou M, Li S, Pathak JL. Pro-inflammatory cytokines and osteocytes. Current osteoporosis reports. 2019;17:97-104.
XI. Mihai S, Codrici E, Popescu ID, Enciu AM, Albulescu L, Necula LG, et al. Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome. J Immunol Res. 2018;2018:2180373.
XII. Cernoch M, Viklicky O. Complement in kidney transplantation. Frontiers in medicine. 2017;4:66.
XIII. Noris M, Remuzzi G, editors. Overview of complement activation and regulation. Seminars in nephrology; 2013: Elsevier.
XIV. Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nature Reviews Nephrology. 2016;12(7):383-401.
XV. Suarez-Fueyo A, Bradley SJ, Klatzmann D, Tsokos GC. T cells and autoimmune kidney disease. Nature Reviews Nephrology. 2017;13(6):329-43.
XVI. Segelmark M, Hellmark T. Autoimmune kidney diseases. Autoimmunity reviews. 2010;9(5):A366-A71.
XVII. Eddy AA. Progression in chronic kidney disease. Advances in chronic kidney disease. 2005;12(4):353-65.
XVIII. Coll E, Botey A, Alvarez L, Poch E, Quintó L, Saurina A, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. American journal of kidney diseases. 2000;36(1):29-34.
XIX. McFarlane P, Cherney D, Gilbert RE, Senior P, Committee DCCPGE. Chronic kidney disease in diabetes. Canadian journal of diabetes. 2018;42:S201-S9.
XX. Cui Z, Zhao J, Jia X-y, Zhu S-n, Zhao M-h. Clinical features and outcomes of anti–glomerular basement membrane disease in older patients. American Journal of Kidney Diseases. 2011;57(4):575-82.
XXI. Kościelska-Kasprzak K, Bartoszek D, Myszka M, Żabińska M, Klinger M. The complement cascade and renal disease. Archivum immunologiae et therapiae experimentalis. 2014;62:47-57.
XXII. Tambur AR, Kosmoliaptsis V, Claas FH, Mannon RB, Nickerson P, Naesens M. Significance of HLA-DQ in kidney transplantation: time to reevaluate human leukocyte antigen–matching priorities to improve transplant outcomes? An expert review and recommendations. Kidney international. 2021;100(5):1012-22.
XXIII. Chew ST, Fitzwilliam J, Indridason OS, Kovalik EC. Role of urine and serum protein electrophoresis in evaluation of nephrotic-range proteinuria. American journal of kidney diseases. 1999;34(1):135-9.
XXIV. Huang X, Wang Y, Xie L, Zhang Y, Tang S, Yin S, et al. IgA nephropathy with anti-neutrophil cytoplasmic antibody seropositivity. Clinical Nephrology. 2015;84(3):156-64.
XXV. Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nature Reviews Rheumatology. 2020;16(10):565-79.

XXVI. Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. The Lancet respiratory medicine. 2020;8(3):304-20.

XXVII. Coppo R, Gianoglio B, Porcellini MG, Maringhini S. Frequency of renal diseases and clinical indications for renal biopsy in children (report of the Italian National Registry of Renal Biopsies in Children). Group of Renal Immunopathology of the Italian Society of Pediatric Nephrology and Group of Renal Immunopathology of the Italian Society of Nephrology. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association. 1998;13(2):293-7.

XXVIII. Okpechi I, Swanepoel C, Duffield M, Mahala B, Wearne N, Alagbe S, et al. Patterns of renal disease in Cape Town South Africa: a 10-year review of a single-centre renal biopsy database. Nephrology Dialysis Transplantation. 2011;26(6):1853-61.

XXIX. Chen M, Kallenberg CG, Zhao M-H. ANCA-negative pauci-immune crescentic glomerulonephritis. Nature Reviews Nephrology. 2009;5(6):313-8.

XXX. Kambham N. Crescentic glomerulonephritis: an update on pauci-immune and anti-GBM diseases. Advances in anatomic pathology. 2012;19(2):111-24.

XXXI. Anders H-J, Saxena R, Zhao M-h, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nature reviews Disease primers. 2020;6(1):7.

XXXII. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The lancet. 2020;395(10229):1033-4.

XXXIII. Afshar-Kharghan V. Atypical hemolytic uremic syndrome. Hematology 2014, the American Society of Hematology Education Program Book. 2016;2016(1):217-25.

XXXIV. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis—a new look at an old entity. New England Journal of Medicine. 2012;366(12):1119-31.

XXXV. Ramachandran R, Kumar V, Nada R, Jha V. Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy. Kidney international. 2015;88(5):1198-9.

XXXVI. Herget-Rosenthal S, editor Imaging techniques in the management of chronic kidney disease: current developments and future perspectives. Seminars in nephrology; 2011: Elsevier.

XXXVII. Wiseman AC. Immunosuppressive Medications. Clin J Am Soc Nephrol. 2016;11(2):332-43.

XXXVIII. Santoro D, Pellicanò V, Visconti L, Trifirò G, Cernaro V, Buemi M. Monoclonal antibodies for renal diseases: current concepts and ongoing treatments. Expert Opinion on Biological Therapy. 2015;15(8):1119-43.

XXXIX. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. American Journal of Transplantation. 2006;6(5):859-66.

XL. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, et al. IL-10, IL-6, and TNF-α: central factors in the altered cytokine network of uremia—the good, the bad, and the ugly. Kidney international. 2005;67(4):1216-33.

XLI. Thurman JM, Le Quintrec M. Targeting the complement cascade: novel treatments coming down the pike. Kidney international. 2016;90(4):746-52.

XLII. Ort M, Dingemanse J, Van den Anker J, Kaufmann P. Treatment of rare inflammatory kidney diseases: drugs targeting the terminal complement pathway. Frontiers in Immunology. 2020;11:599417.

XLIII. Fan X-L, Zhang Y, Li X, Fu Q-L. Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cellular and molecular life sciences. 2020;77:2771-94.

XLIV. Wang M, Yuan Q, Xie L. Mesenchymal stem cell-based immunomodulation: properties and clinical application. Stem cells international. 2018;2018.

XLV. Pusey CD, Levy JB. Plasmapheresis in immunologic renal disease. Blood purification. 2012;33(1-3):190-8.

XLVI. Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends in immunology. 2008;29(12):608-15.

XLVII. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nature Reviews Immunology. 2013;13(3):176-89.

XLVIII. Arend WP. The mode of action of cytokine inhibitors. The Journal of Rheumatology Supplement. 2002;65:16-21.

XLIX. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nature reviews Drug discovery. 2017;16(12):843-62.

L. Gadina M, Gazaniga N, Vian L, Furumoto Y. Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases. Journal of Autoimmunity. 2017;85:20-31.

LI. Wu X, Jiang J, Gu Z, Zhang J, Chen Y, Liu X. Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress. Stem cell research & therapy. 2020;11(1):1-16.